

Tirzepatide 30 mg + MOTS-C 32 mg
Pens bought separately IDR 6,400,000
Original documents
Open the original PDF published with this product. Check the report’s batch reference against the pack you are ordering.
Need a report for a particular batch? Ask our team on WhatsApp.
About the compound
Tirzepatide acts at GIP and GLP-1 receptors. Research on these pathways examines appetite, glucose regulation and body weight. The SURMOUNT-1 study below investigated weight management in adults with obesity.
The two Body Pharm formats contain different total amounts per pen. Select 30 mg or 60 mg to compare the price, packaging photos and matching laboratory report. The amount printed on a pen is not a personal dosing instruction.
These sources describe the compounds and study settings, rather than clinical testing of this finished Body Pharm pen.
For research and educational use only. Not for human or veterinary consumption. These products are research compounds and are not approved as medicines.